FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382363527> ?p ?o ?g. }

• W4382363527 endingPage "3351" @default.
• W4382363527 startingPage "3340" @default.
• W4382363527 abstract "Abstract Purpose: Plasma circulating tumor DNA (ctDNA) analysis is used for genotyping advanced non–small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to predict outcomes. Patients and Methods: This was a retrospective, exploratory analysis of two phase III trials [AURA3 (NCT02151981), FLAURA (NCT02296125)]. All patients had EGFR mutation-positive (EGFRm; ex19del or L858R) advanced NSCLC; AURA3 also included T790M-positive NSCLC. Osimertinib (FLAURA, AURA3), or comparator EGFR–tyrosine kinase inhibitor (EGFR-TKI; gefitinib/erlotinib; FLAURA), or platinum-based doublet chemotherapy (AURA3) was given. Plasma EGFRm was analyzed at baseline and Weeks 3/6 by droplet digital PCR. Outcomes were assessed by detectable/non-detectable baseline plasma EGFRm and plasma EGFRm clearance (non-detection) at Weeks 3/6. Results: In AURA3 (n = 291), non-detectable versus detectable baseline plasma EGFRm had longer median progression-free survival [mPFS; HR, 0.48; 95% confidence interval (CI), 0.33–0.68; P &lt; 0.0001]. In patients with Week 3 clearance versus non-clearance (n = 184), respectively, mPFS (months; 95% CI) was 10.9 (8.3–12.6) versus 5.7 (4.1–9.7) with osimertinib and 6.2 (4.0–9.7) versus 4.2 (4.0–5.1) with platinum-pemetrexed. In FLAURA (n = 499), mPFS was longer with non-detectable versus detectable baseline plasma EGFRm (HR, 0.54; 95% CI, 0.41–0.70; P &lt; 0.0001). For Week 3 clearance versus non-clearance (n = 334), respectively, mPFS was 19.8 (15.1 to not calculable) versus 11.3 (9.5–16.5) with osimertinib and 10.8 (9.7–11.1) versus 7.0 (5.6–8.3) with comparator EGFR-TKI. Similar outcomes were observed by Week 6 clearance/non-clearance. Conclusions: Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC." @default.
• W4382363527 created "2023-06-29" @default.
• W4382363527 creator A5001577825 @default.
• W4382363527 creator A5007121755 @default.
• W4382363527 creator A5008790176 @default.
• W4382363527 creator A5023192928 @default.
• W4382363527 creator A5034739279 @default.
• W4382363527 creator A5038306289 @default.
• W4382363527 creator A5045263771 @default.
• W4382363527 creator A5045665778 @default.
• W4382363527 creator A5047714811 @default.
• W4382363527 creator A5048313601 @default.
• W4382363527 creator A5053871500 @default.
• W4382363527 creator A5055204234 @default.
• W4382363527 creator A5057704753 @default.
• W4382363527 creator A5059123004 @default.
• W4382363527 creator A5059355812 @default.
• W4382363527 creator A5063661642 @default.
• W4382363527 creator A5064697305 @default.
• W4382363527 creator A5070375776 @default.
• W4382363527 creator A5072724155 @default.
• W4382363527 creator A5075347427 @default.
• W4382363527 creator A5077287358 @default.
• W4382363527 creator A5088178599 @default.
• W4382363527 date "2023-06-28" @default.
• W4382363527 modified "2023-10-03" @default.
• W4382363527 title "Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA" @default.
• W4382363527 cites W2070059866 @default.
• W4382363527 cites W2088540000 @default.
• W4382363527 cites W2107482271 @default.
• W4382363527 cites W2171237493 @default.
• W4382363527 cites W2477306026 @default.
• W4382363527 cites W2560717039 @default.
• W4382363527 cites W2612476367 @default.
• W4382363527 cites W2766316939 @default.
• W4382363527 cites W2770828094 @default.
• W4382363527 cites W2784623697 @default.
• W4382363527 cites W2879254181 @default.
• W4382363527 cites W2883896246 @default.
• W4382363527 cites W2887416920 @default.
• W4382363527 cites W2888877308 @default.
• W4382363527 cites W2893241945 @default.
• W4382363527 cites W2979140055 @default.
• W4382363527 cites W2990041408 @default.
• W4382363527 cites W2991273563 @default.
• W4382363527 cites W2997144226 @default.
• W4382363527 cites W3013265767 @default.
• W4382363527 cites W3087210493 @default.
• W4382363527 cites W3091987693 @default.
• W4382363527 cites W3178692152 @default.
• W4382363527 cites W3182408948 @default.
• W4382363527 cites W3194596778 @default.
• W4382363527 cites W4252867417 @default.
• W4382363527 cites W4302024868 @default.
• W4382363527 cites W4317761498 @default.
• W4382363527 doi "https://doi.org/10.1158/1078-0432.ccr-22-3146" @default.
• W4382363527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37379430" @default.
• W4382363527 hasPublicationYear "2023" @default.
• W4382363527 type Work @default.
• W4382363527 citedByCount "1" @default.
• W4382363527 countsByYear W43823635272023 @default.
• W4382363527 crossrefType "journal-article" @default.
• W4382363527 hasAuthorship W4382363527A5001577825 @default.
• W4382363527 hasAuthorship W4382363527A5007121755 @default.
• W4382363527 hasAuthorship W4382363527A5008790176 @default.
• W4382363527 hasAuthorship W4382363527A5023192928 @default.
• W4382363527 hasAuthorship W4382363527A5034739279 @default.
• W4382363527 hasAuthorship W4382363527A5038306289 @default.
• W4382363527 hasAuthorship W4382363527A5045263771 @default.
• W4382363527 hasAuthorship W4382363527A5045665778 @default.
• W4382363527 hasAuthorship W4382363527A5047714811 @default.
• W4382363527 hasAuthorship W4382363527A5048313601 @default.
• W4382363527 hasAuthorship W4382363527A5053871500 @default.
• W4382363527 hasAuthorship W4382363527A5055204234 @default.
• W4382363527 hasAuthorship W4382363527A5057704753 @default.
• W4382363527 hasAuthorship W4382363527A5059123004 @default.
• W4382363527 hasAuthorship W4382363527A5059355812 @default.
• W4382363527 hasAuthorship W4382363527A5063661642 @default.
• W4382363527 hasAuthorship W4382363527A5064697305 @default.
• W4382363527 hasAuthorship W4382363527A5070375776 @default.
• W4382363527 hasAuthorship W4382363527A5072724155 @default.
• W4382363527 hasAuthorship W4382363527A5075347427 @default.
• W4382363527 hasAuthorship W4382363527A5077287358 @default.
• W4382363527 hasAuthorship W4382363527A5088178599 @default.
• W4382363527 hasBestOaLocation W43823635272 @default.
• W4382363527 hasConcept C104317684 @default.
• W4382363527 hasConcept C121608353 @default.
• W4382363527 hasConcept C126322002 @default.
• W4382363527 hasConcept C135763542 @default.
• W4382363527 hasConcept C143998085 @default.
• W4382363527 hasConcept C2776256026 @default.
• W4382363527 hasConcept C2777626846 @default.
• W4382363527 hasConcept C2777930144 @default.
• W4382363527 hasConcept C2778087573 @default.
• W4382363527 hasConcept C2778820342 @default.
• W4382363527 hasConcept C2779438470 @default.
• W4382363527 hasConcept C2780580887 @default.
• W4382363527 hasConcept C31467283 @default.

• next